{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:56:29Z","timestamp":1777521389035,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.xops.2025.100759","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T21:36:38Z","timestamp":1741815398000},"page":"100759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sozinibercept (Anti-VEGF-C\/-D) Combined with Ranibizumab for Polypoidal Choroidal Vasculopathy: Phase IIb Predefined Subgroup Analysis"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian M.","family":"Leitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan E.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Slakter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.100759_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV)","volume":"10","author":"Yannuzzi","year":"1990","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100759_bib2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00006982-199515020-00003","article-title":"Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy","volume":"15","author":"Spaide","year":"1995","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100759_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","article-title":"Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?","volume":"29","author":"Laude","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2025.100759_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100759_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","article-title":"Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","volume":"53","author":"Wong","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2025.100759_bib6","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/IAE.0b013e31823beb14","article-title":"Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings","volume":"32","author":"Khan","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100759_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/01.iae.0000249386.63482.05","article-title":"Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy","volume":"27","author":"Sato","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100759_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajo.2014.05.004","article-title":"Comparison of exudative age-related macular degeneration subtypes in Japanese and French patients: multicenter diagnosis with multimodal imaging","volume":"158","author":"Coscas","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100759_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/OPTH.S385827","article-title":"Polypoidal choroidal vasculopathy: an update on diagnosis and treatment","volume":"17","author":"Sen","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2025.100759_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100759_bib11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100759_bib12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/eye.2011.324","article-title":"Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy","volume":"26","author":"Cho","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2025.100759_bib13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.100759_bib14","doi-asserted-by":"crossref","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","article-title":"Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan","volume":"13","author":"Mukai","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2025.100759_bib16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.exer.2006.05.007","article-title":"The regulation of vascular endothelial growth factors (VEGF-A, -C, and -D) expression in the retinal pigment epithelium","volume":"83","author":"Ikeda","year":"2006","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2025.100759_bib17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cardiores.2004.12.002","article-title":"The biology of vascular endothelial growth factors","volume":"65","author":"Tammela","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.xops.2025.100759_bib18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/01.RES.0000118600.91698.BB","article-title":"Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability","volume":"94","author":"Cao","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.xops.2025.100759_bib19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrm2183","article-title":"Molecular regulation of angiogenesis and lymphangiogenesis","volume":"8","author":"Adams","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.xops.2025.100759_bib20","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1074\/jbc.273.12.6599","article-title":"A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities","volume":"273","author":"Joukov","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.xops.2025.100759_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2013.12.004","article-title":"Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression","volume":"346","author":"Li","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.xops.2025.100759_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077117","article-title":"The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer","volume":"8","author":"Lieu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2025.100759_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-010-0480-6","article-title":"Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells","volume":"104","author":"Grau","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.xops.2025.100759_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.oret.2017.04.004","article-title":"Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers","volume":"2","author":"Cabral","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2025.100759_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.exer.2015.12.014","article-title":"Response to anti-VEGF-A treatment of endothelial cells in vitro","volume":"146","author":"Puddu","year":"2016","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2025.100759_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40942-017-0084-9","article-title":"Retinal and choroidal angiogenesis: a review of new targets","volume":"3","author":"Cabral","year":"2017","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.xops.2025.100759_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12886-019-1278-8","article-title":"Comparison of cytokine levels in the aqueous humor of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration patients","volume":"20","author":"Zhou","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.xops.2025.100759_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.oret.2019.10.008","article-title":"Phase 1 study of OPT-302 inhibition of vascular endothelial growth factors C and D for neovascular age-related macular degeneration","volume":"4","author":"Dugel","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2025.100759_bib29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2023.02.001","article-title":"A randomized controlled trial of OPT-302, a VEGF-C\/D inhibitor for neovascular age-related macular degeneration","volume":"130","author":"Jackson","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100759_bib30","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1167\/iovs.12-9619","article-title":"Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"53","author":"Jirarattanasopa","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100759_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/aos.12653","article-title":"Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration","volume":"93","author":"Shin","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2025.100759_bib32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ajo.2014.01.019","article-title":"Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration","volume":"157","author":"Kang","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100759_bib33","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/IAE.0000000000001758","article-title":"Choroidal vascular hyperpermeability as apredictor of treatment response for polypoidal choroidal vasculopathy","volume":"38","author":"Yanagi","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100759_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/OPTH.S125676","article-title":"Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis","volume":"11","author":"Spooner","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2025.100759_bib37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2025.100759_bib38","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2025.100759_bib39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaophthalmol.2019.0565","article-title":"Sensitivity and specificity of potential diagnostic features detected using fundus photography, optical coherence tomography, and fluorescein angiography for polypoidal choroidal vasculopathy","volume":"137","author":"Chaikitmongkol","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.100759_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2025.100144","article-title":"Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS)","volume":"14","author":"Ruamviboonsuk","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila)"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525000570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525000570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:43:32Z","timestamp":1772048612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914525000570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2666914525000570"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.100759","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sozinibercept (Anti-VEGF-C\/-D) Combined with Ranibizumab for Polypoidal Choroidal Vasculopathy: Phase IIb Predefined Subgroup Analysis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.100759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100759"}}